Skip to main content

Advertisement

SpringerLink
Log in

A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer

  • Brief Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Fulvestrant is a highly active systemic therapy in patients with metastatic hormone receptor positive breast cancer. Preclinical work suggested potential synergy of fulvestrant in combination with aromatase inhibitor therapy and delayed development of endocrine resistance. The purpose of this meta-analysis is to evaluate the effectiveness of fulvestrant plus anastrozole, compared to anastrozole alone, as first line treatment of postmenopausal stage IV hormone receptor positive, HER2-negative breast cancer. The literature search was performed using PubMed, Google Scholar, Embase, ASCO, and ESMO to search for abstracts published during the last 10 years using relevant keywords. Two prospective randomized clinical trials were found to fulfill the search criteria for combination of anastrozole plus fulvestrant versus anastrozole alone. Meta-estimates were calculated by combining study estimates using the DerSimonian and Laird random effects model. The linear mixed-effects model was used to generate 95 % prediction intervals (PIs) for study-specific hazard and odds ratios. Pooled hazard ratio for progression-free survival is 0.88 (95 % CI 0.72–1.09, 95 % PI 0.65–1.21), overall survival 0.88 (95 % CI 0.72–1.08, 95 % PI 0.68–1.14) and pooled odds ratio for response rate is 1.13 (95 % CI 0.79–1.63, 95 % PI 0.78–1.65). A non-significant trend was observed with anastrozole plus fulvestrant being only marginally better than anastrozole alone in the endpoints of: progression-free survival, overall survival, and response rates. Based on these data, there is not solid evidence that the addition of fulvestrant at a dose of 250 mg monthly is better than anastrozole alone as first line therapy in women with postmenopausal hormone receptor positive breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Society AC (2013) Cancer facts and figures 2013. American Cancer Society, Atlanta

    Google Scholar 

  2. Montero AJ, Eapen S, Gorin B, Adler P (2012) The economic burden of metastatic breast cancer: a U.S. managed care perspective. Breast Cancer Res Treat 134(2):815–822

    Article  PubMed  Google Scholar 

  3. Johnston SR, Dowsett M (2003) Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 3(11):821–831

    Article  PubMed  CAS  Google Scholar 

  4. Ring A, Dowsett M (2004) Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11(4):643–658

    Article  PubMed  CAS  Google Scholar 

  5. Wakeling AE (2000) Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer 7(1):17–28

    Article  PubMed  CAS  Google Scholar 

  6. Montemurro F, Rossi V, Geuna E, Valabrega G, Martinello R, Milani A, Aglietta M (2012) Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer. Expert Opin Pharmacother 13(15):2143–2156

    Article  PubMed  CAS  Google Scholar 

  7. Tinoco G, Warsch S, Gluck S, Avancha K, Montero AJ (2013) Treating breast cancer in the 21st century: emerging biological therapies. J Cancer 4(2):117–132

    Article  PubMed  Google Scholar 

  8. Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff R (2008) Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res 68(18):7493–7501

    Article  PubMed  CAS  Google Scholar 

  9. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I et al (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20(16):3386–3395

    Article  PubMed  CAS  Google Scholar 

  10. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C (2002) Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20(16):3396–3403

    Article  PubMed  CAS  Google Scholar 

  11. Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM (2003) Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 97(3):545–553

    Article  PubMed  Google Scholar 

  12. Dawood S, Broglio K, Ensor J, Hortobagyi GN, Giordano SH (2010) Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol 21(11):2169–2174

    Article  PubMed  CAS  Google Scholar 

  13. Planchat E, Abrial C, Thivat E, Mouret-Reynier MA, Kwiatkowski F, Pomel C, Wang-Lopez Q, Chollet P, Nabholtz JM, Durando X (2011) Late lines of treatment benefit survival in metastatic breast cancer in current practice? Breast 20(6):574–578

    Article  PubMed  CAS  Google Scholar 

  14. Rugo HS, Taylor D, Sanon M, Clements K, Balu S, Faria C, Teitelbaum A (2011) P1-08-07: survival in US women following an indication of metastatic breast cancer diagnosis and chemotherapy initiation: a SEER-medicare analysis. Cancer Res 71(24 Suppl): P1-08-07

  15. Wakeling AE, Dukes M, Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51(15):3867–3873

    PubMed  CAS  Google Scholar 

  16. Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AM (2005) Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res 65(12):5439–5444

    Article  PubMed  CAS  Google Scholar 

  17. Macedo LF, Sabnis GJ, Goloubeva OG, Brodie A (2008) Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model. Cancer Res 68(9):3516–3522

    Article  PubMed  CAS  Google Scholar 

  18. Bergh J, Jonsson PE, Lidbrink EK, Trudeau M, Eiermann W, Brattstrom D, Lindemann JP, Wiklund F, Henriksson R (2012) FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 30(16):1919–1925

    Article  PubMed  CAS  Google Scholar 

  19. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB et al (2012) Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 367(5):435–444

    Article  PubMed  CAS  Google Scholar 

  20. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188

    Article  PubMed  CAS  Google Scholar 

  21. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558

    Article  PubMed  Google Scholar 

  22. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR et al (2010) Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 28(30):4594–4600

    Article  PubMed  Google Scholar 

  23. Ramaekers R, Jabbour M, Copur MS (2012) Anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 367(17):1662–1663 author reply 1663–1664

    Article  PubMed  CAS  Google Scholar 

  24. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520–529

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflicts of interest in this study.

Author information

Authors and Affiliations

  1. Duke-National University of Singapore Graduate Medical School, Singapore, Singapore

    Pui San Tan & Benjamin Haaland

  2. Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA

    Alberto J. Montero

  3. Johns Hopkins Singapore International Medical Centre, 11 Jalan Tan Tock Seng, Level 1, Singapore, 308843, Singapore

    Gilberto Lopes

  4. Johns Hopkins University, Baltimore, MD, USA

    Gilberto Lopes

Authors
  1. Pui San Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Benjamin Haaland
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alberto J. Montero
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gilberto Lopes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gilberto Lopes.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tan, P.S., Haaland, B., Montero, A.J. et al. A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer. Breast Cancer Res Treat 138, 961–965 (2013). https://doi.org/10.1007/s10549-013-2495-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-013-2495-0

Keywords

Search

Navigation